BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int 2021. [PMID: 34953098 DOI: 10.1111/liv.15139] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A. MAFLD and CKD: An Updated Narrative Review. IJMS 2022;23:7007. [DOI: 10.3390/ijms23137007] [Reference Citation Analysis]
2 Androutsakos T, Voulgaris TA, Bakasis A, Koutsompina M, Chatzis L, Argyropoulou OD, Pezoulas V, Fotiadis DI, Papatheodoridis G, Tzioufas AG, Goules AV. Liver Fibrosis in Primary Sjögren’s Syndrome. Front Immunol 2022;13:889021. [DOI: 10.3389/fimmu.2022.889021] [Reference Citation Analysis]
3 Luo L, Ye J, Shao C, Lin Y, Sun Y, Feng S, Wang W, Zhong B. Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection. Nutrients 2022;14:2114. [DOI: 10.3390/nu14102114] [Reference Citation Analysis]
4 Attia D, Gomaa A, Abdel Alem S. Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD. Hepatology 2022. [PMID: 35532891 DOI: 10.1002/hep.32563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 van Kleef LA, de Knegt RJ. The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach? Hepatology 2022. [PMID: 35503710 DOI: 10.1002/hep.32552] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022;7:388-90. [PMID: 35248211 DOI: 10.1016/S2468-1253(22)00062-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
7 Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-peralta F. Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. JCM 2022;11:968. [DOI: 10.3390/jcm11040968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Santos JPMD, Maio MC, Lemes MA, Laurindo LF, Haber JFDS, Bechara MD, Prado PSD Jr, Rauen EC, Costa F, Pereira BCA, Flato UAP, Goulart RA, Chagas EFB, Barbalho SM. Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future. Int J Mol Sci 2022;23:498. [PMID: 35008925 DOI: 10.3390/ijms23010498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]